AUTOLOGOUS STEM CELL TRANSPLANT
FOR MYELOMA IN CHINA
Prepared by the CancerFax oncology navigation team. Updated regularly based on treatment access and clinical availability.
analyticsAt a Glance
- check_circleAutologous stem cell transplant remains first-line consolidation for eligible myeloma patients
- check_circleChina offers high-quality autologous transplant programmes at significantly lower cost than the West
- check_circlePost-transplant maintenance with lenalidomide or bortezomib is standard at leading Chinese centres
- check_circleCancerFax assists with case review, centre selection, and full logistics for transplant in China
Why Patients Consider ASCT in China
Multiple myeloma is a treatable but currently incurable cancer of plasma cells. Modern induction regimens, often combining a proteasome inhibitor, an immunomodulatory drug, and a CD38 antibody, can produce deep responses in many newly diagnosed patients. For patients who are fit enough, consolidating that response with a high-dose melphalan transplant has been shown over decades of trials to lengthen progression-free survival. Maintenance therapy, usually with lenalidomide, then continues for an extended period to keep the disease under control. Families look at China for myeloma transplant for several practical reasons. The major hematology centres in Beijing, Tianjin, Shanghai, Hangzhou, and other cities perform large volumes of transplants every year and have well-organised supportive care for engraftment-period complications. Cost is generally meaningfully lower than in North America, Western Europe, or Singapore, while the standard of care for ASCT itself is broadly aligned with international guidelines. China is also one of the leading global centres for BCMA CAR T-cell therapy for relapsed myeloma, which gives families access to a structured second-line plan if the disease comes back after transplant.
What ASCT for Myeloma Involves
An autologous transplant uses the patient's own stem cells, not a donor's. The stem cells themselves do not treat the myeloma. The treatment is the high-dose melphalan chemotherapy given just before reinfusion. The transplanted stem cells exist to rescue the bone marrow from that high-dose chemotherapy and allow blood counts to recover. The full ASCT pathway is usually broken down into the following phases. The exact timeline depends on the centre's protocol and the patient's response. Single, tandem, and salvage transplant Most newly diagnosed transplant-eligible patients undergo a single autologous transplant. In selected high-risk patients, particularly those with adverse cytogenetics such as del(17p), t(4;14), or t(14;16), the team may discuss a tandem transplant, where a second ASCT is performed three to six months after the first. A salvage transplant may be considered later in the disease course for patients who had a long remission after their first transplant and relapse with myeloma that is still chemotherapy-sensitive. Whether tandem or salvage transplant is appropriate depends on the patient's specific case and is decided by the treating hematologist.
Who May Be Suitable
ASCT is generally considered for patients who meet a combination of disease-related and patient-related criteria. The exact thresholds vary by centre, but the case is usually assessed on: Patients who are not candidates for ASCT, often due to age or comorbidity, are managed with continuous combination therapy and may still be eligible for advanced options such as BCMA CAR T-cell therapy or bispecific antibodies if the disease relapses. The role of CancerFax in such cases is to help the family understand the realistic alternatives rather than pushing transplant when it is not appropriate.
Confirmed diagnosis of multiple myeloma (active myeloma requ
Confirmed diagnosis of multiple myeloma (active myeloma requiring treatment) on bone marrow biopsy and serum/urine protein studies
Risk profile based on FISH cytogenetics and ISS or R-ISS sta
Risk profile based on FISH cytogenetics and ISS or R-ISS staging
Response to induction therapy (very good partial response or
Response to induction therapy (very good partial response or better is usually preferred, although patients in partial response may still be considered)
Age and fitness โ ASCT is most often offered up to around 65
Age and fitness โ ASCT is most often offered up to around 65โ70 years of age, with selected fit patients beyond that age also considered
Adequate cardiac, pulmonary, liver, and kidney function โ hi
Adequate cardiac, pulmonary, liver, and kidney function โ high-dose melphalan can still be given (at reduced doses) in many patients with kidney impairment
Performance status that allows the patient to tolerate sever
Performance status that allows the patient to tolerate several weeks of intensive treatment
Absence of uncontrolled active infection
Absence of uncontrolled active infection
Sufficient stem cell yield from mobilisation, or willingness
Sufficient stem cell yield from mobilisation, or willingness to attempt re-mobilisation if needed
Documents Usually Required for Review
A meaningful transplant assessment depends on having a complete and current case file. The records most centres in China will want to see include: If reports are in a regional language, English translations help the review move faster. Where reports are missing, our team helps the family identify exactly what to ask the treating hospital for before submission.
Latest medical summary and diagnosis report
Latest medical summary and diagnosis report
Bone marrow aspirate and biopsy reports, including plasma ce
Bone marrow aspirate and biopsy reports, including plasma cell percentage
FISH cytogenetics and karyotype reports for myeloma-specific
FISH cytogenetics and karyotype reports for myeloma-specific abnormalities (such as del(17p), t(4;14), t(14;16), gain(1q), del(1p))
Serum protein electrophoresis (SPEP), serum immunofixation,
Serum protein electrophoresis (SPEP), serum immunofixation, serum free light chains (kappa and lambda with ratio), and 24-hour urine studies
Quantitative immunoglobulins and beta-2 microglobulin
Quantitative immunoglobulins and beta-2 microglobulin
Albumin, LDH, calcium, creatinine, and full blood counts
Albumin, LDH, calcium, creatinine, and full blood counts
Liver and kidney function tests
Liver and kidney function tests
Imaging
whole-body low-dose CT, PET CT, or whole-body MRI to assess bone disease
Echocardiogram or 2D-echo and pulmonary function tests, wher
Echocardiogram or 2D-echo and pulmonary function tests, where available
Infection screening
hepatitis B, hepatitis C, HIV, syphilis, CMV, and tuberculosis status
Full record of induction therapy with regimen, doses, dates,
Full record of induction therapy with regimen, doses, dates, cycles, and best response achieved
Any prior radiation, surgical, or supportive care notes (for
Any prior radiation, surgical, or supportive care notes (for example for plasmacytoma or bone disease)
How CancerFax Helps
CancerFax supports families considering myeloma transplant in China through a structured pathway:
Case review and disease understanding. We review the diagnos
Case review and disease understanding. We review the diagnosis, FISH cytogenetics, response to induction, and current status to confirm whether transplant is a realistic next step or whether the case is better served by a different option such as continued combination therapy or, in selected relapsed cases, BCMA CAR T-cell therapy.
Centre matching. Records are shared with appropriate hematol
Centre matching. Records are shared with appropriate hematology and transplant teams in China for structured pre-assessment. We help families understand the differences between centres in terms of volume, supportive care, language access, and admission timelines.
Treatment planning and cost clarity. Once a centre accepts t
Treatment planning and cost clarity. Once a centre accepts the case for management, the family receives a planning package covering the proposed sequence (mobilisation, conditioning, transplant, recovery), expected total stay, and a realistic cost range with assumptions clearly listed.
Visa, travel, and admission coordination. Medical visa invit
Visa, travel, and admission coordination. Medical visa invitation, accommodation suitable for an immunocompromised patient, interpreter support, and admission window are aligned so that arrival is smooth and the patient is not exposed to unnecessary delays.
On-ground support during transplant. From admission through
On-ground support during transplant. From admission through discharge, we stay involved as a single point of contact for the family, translating medical updates, supporting communication when the plan changes, and helping the family understand what is happening during engraftment.
Discharge and home-country follow-up. Before the family leav
Discharge and home-country follow-up. Before the family leaves, we help compile the transplant summary, day-of-transplant details, conditioning regimen, complications, growth factor support, and recommended maintenance plan in a clean format the local hematologist can use to continue care.
How ASCT Compares With BCMA CAR T-Cell Therapy
Families exploring myeloma options in China often ask how transplant compares with BCMA CAR T-cell therapy, since China is one of the leading global centres for CAR T in myeloma. The two are not direct substitutes. They sit at different points in the treatment pathway and answer different questions. For most newly diagnosed transplant-eligible patients, ASCT remains the standard consolidation step. CAR T becomes more relevant later in the journey if the disease relapses. Families do not have to choose between them today; the decision depends on the stage of disease, prior treatment, and the treating team's assessment.
Where This May Be Available in China
Several major centres in China have well-established myeloma transplant programmes, often paired with active hematology research and CAR T-cell therapy capability. Examples that families commonly ask about include: The most appropriate centre for a given patient depends on diagnosis, risk profile, prior treatment, urgency, and the family's practical situation. CancerFax helps families select a centre that fits the case rather than choosing by name alone.
Institute of Hematology and Blood Diseases Hospital, Chinese
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin) โ a leading national hematology centre
Peking University People's Hospital, Beijing โ well-known fo
Peking University People's Hospital, Beijing โ well-known for hematology and transplant
Ruijin Hospital, Shanghai โ long-standing leukaemia and myel
Ruijin Hospital, Shanghai โ long-standing leukaemia and myeloma programmes
First Affiliated Hospital of Zhejiang University, Hangzhou โ
First Affiliated Hospital of Zhejiang University, Hangzhou โ strong hematology and cell therapy services
Shanghai GoBroad Cancer Institute and Royal Lee Cancer Hospi
Shanghai GoBroad Cancer Institute and Royal Lee Cancer Hospital network โ experienced in transplant and CAR T-cell therapy
Other university and provincial cancer hospitals with transp
Other university and provincial cancer hospitals with transplant accreditation
Frequently Asked Questions
Answers to common questions from patients and families.
Is autologous transplant a cure for multiple myeloma?
No. Autologous transplant is not a cure. It is used to deepen the response after induction therapy and prolong the time before the disease comes back. Most patients still need maintenance therapy afterwards, and many will eventually relapse and require further treatment. Transplant is one important step in a longer treatment journey, not a single fix. Decisions about whether transplant is right for an individual depend on disease risk, response to induction, age, fitness, and patient preference.
When during my treatment is transplant usually done?
Transplant is most often performed after four to six cycles of induction therapy, once the disease has responded well and the patient is in a stable condition. Some teams collect and freeze stem cells after induction and proceed straight to transplant; others freeze cells for later use and continue with maintenance first. The exact timing depends on the centre's protocol, the depth of response, the cytogenetic risk profile, and the patient's overall fitness.
How long do I need to stay in China for an autologous transplant?
Most international patients plan for six to ten weeks in country for a single autologous transplant. This includes pre-transplant workup, mobilisation, stem cell collection, conditioning chemotherapy, transplant day, the engraftment period, and early recovery. Tandem transplant adds significantly to the timeline. Final stay duration depends on how the patient recovers and whether complications arise. We share a realistic time plan in writing before any travel commitment.
Will I need a donor for an autologous transplant?
No. An autologous transplant uses the patient's own stem cells, collected from the bloodstream after mobilisation with growth factors. There is no need for a sibling, family, or unrelated donor. This is one of the practical advantages of autologous transplant and is part of the reason it is offered to so many myeloma patients. Donor (allogeneic) transplant is sometimes considered in younger high-risk patients or in special situations, but it is not standard for most myeloma cases.
Can patients with kidney problems still have an autologous transplant?
In many cases, yes, although the team will adjust the conditioning regimen. High-dose melphalan can usually still be given at a reduced dose (often 140 mg/mยฒ instead of 200 mg/mยฒ) in patients with significant kidney impairment, including those on dialysis. Eligibility is decided after a full review of kidney function, response to induction, and overall fitness. Patients with kidney involvement should ensure that recent creatinine, eGFR, and 24-hour urine reports are part of the records shared.
What happens if my disease comes back after transplant?
Many patients eventually relapse after autologous transplant, sometimes years later. At that point the treatment options depend on the duration of remission, prior therapies, and current disease status. Options may include new combination regimens with different drug classes, BCMA CAR T-cell therapy, bispecific antibody therapy, salvage chemotherapy, or in selected cases a second autologous transplant. China is one of the leading global centres for BCMA CAR T-cell therapy in myeloma, and CancerFax can help families re-engage when the disease behaviour changes.
How much does autologous transplant for myeloma cost in China?
Cost varies by centre, room category, complications, and whether single or tandem transplant is planned. In general, ASCT in China is meaningfully less expensive than in North America, Western Europe, or Singapore for equivalent care. Cost categories include workup, mobilisation, stem cell collection and storage, conditioning chemotherapy, the transplant admission, supportive care, accommodation, and interpreter support. CancerFax shares written cost ranges with clear assumptions before travel decisions are made.
Can CancerFax guarantee that my case will be accepted for transplant?
No. Acceptance depends on the transplant centre's review of the case, the patient's clinical condition, and the response to induction therapy. CancerFax prepares the case carefully and submits it through appropriate channels, but the medical decision rests with the treating team. If transplant is not appropriate at this point, we help families understand why and explore realistic alternatives, such as continued combination therapy or, in selected relapsed cases, BCMA CAR T-cell therapy.
Reference Data
Structured reference data summarizing key information for this topic.
| Phase | What happens | Typical duration |
|---|---|---|
| Induction therapy | Typically four to six cycles of a triplet or quadruplet regimen (for example VRd, VCd, KRd, or Dara-VRd) given before transplant to bring the myeloma under control. | Usually 3โ6 months, often started in the home country. |
| Pre-transplant workup | Confirms fitness for transplant: cardiac function, lung function, kidney function, infection screening, dental review, repeat marrow and imaging where needed. | 1โ2 weeks at the transplant centre. |
| Stem cell mobilisation | G-CSF (often with cyclophosphamide) and, if needed, plerixafor are used to push stem cells out of the marrow into the blood for collection. | Around 5โ10 days. |
| Stem cell collection (apheresis) | Stem cells are collected from the bloodstream over one to three sessions and frozen for later use. | 1โ3 days. |
| Conditioning chemotherapy | High-dose melphalan, usually at 200 mg/mยฒ (reduced for patients with kidney impairment), is given over one to two days. | 1โ2 days. |
| Stem cell reinfusion (Day 0) | The previously collected stem cells are thawed and reinfused into the bloodstream, where they find their way back to the bone marrow. | A few hours. |
| Engraftment and recovery | Blood counts drop, then recover as the new stem cells settle in. Patients are watched closely for infections, mucositis, and other complications. | Usually 2โ4 weeks of inpatient or close outpatient care. |
| Maintenance therapy | Most patients continue lenalidomide, sometimes with bortezomib in high-risk disease, for an extended period after transplant. | Months to years, usually managed in the home country. |
Reference Data
Structured reference data summarizing key information for this topic.
| Question | Autologous transplant | BCMA CAR T-cell therapy |
|---|---|---|
| Where it usually fits | After induction therapy in newly diagnosed transplant-eligible patients, or as salvage in selected relapsed patients. | Most often in relapsed or refractory myeloma after multiple prior lines, including after transplant. Earlier-line use is being studied. |
| How it works | High-dose melphalan clears residual myeloma; the patient's own stem cells rescue the bone marrow. | The patient's own T cells are engineered to recognise BCMA on myeloma cells and infused back to attack the cancer. |
| Goal of treatment | Deepen response and prolong remission. Not curative. | Deep, often durable responses in heavily pre-treated patients. Not curative. |
| Typical stay | 6โ10 weeks in country for a single transplant. | Often 8โ12 weeks, depending on protocol, manufacturing, and recovery. |
| Key risks | Infections, mucositis, cytopenias, transfusion needs, rare secondary malignancy. | Cytokine release syndrome, neurotoxicity, prolonged cytopenias, infection risk. |
| Eligibility limits | Age, organ function, response to induction, fitness for high-dose chemotherapy. | Prior lines of therapy, BCMA expression, organ function, disease tempo, trial-specific criteria. |
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Understanding Your Options?
If you or a family member is considering autologous stem cell transplant for multiple myeloma, CancerFax can help organise the medical records, review whether transplant is the right next step, and connect the case with experienced hematology centres in China. If a different pathway, such as continued combination therapy or BCMA CAR T-cell therapy, is more appropriate, we will tell you that openly
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.